Conventional magnetic resonance imaging (MRI) has a pivotal role in diagnosis and post-treatment management of glioblastoma, however it has limitations. This work investigates the use of advanced MRI techniques that assess the tumour microenvironment, and artificial intelligence (AI) techniques that compute quantitative features, as potential imaging biomarkers in key clinical issues faced by clinicians, through several retrospective studies. Results show that advanced multiparametric MRI is superior to current standard-of-care imaging for the diagnosis of glioblastoma, and in treatment response assessment. Results of AI techniques on pre-operative imaging show the ability to differentiate between glioblastoma and metastasis with an accuracy of 88.7%, prediction of overall survival with a high level of accuracy, and stratification of patients into high- and low-level groups of MGMT promoter methylation with accuracies between 45-67%. In the early post-treatment phase, AI analysis of imaging can distinguish between disease progression and pseudoprogression with an accuracy of 73.7%, compared to neuroradiologist accuracy of 32.9%. Integrating these techniques into routine clinical practice is essential to improve patient outcomes. Further work is required to validate advanced imaging and AI biomarkers, towards the longer-term goal of using these as clinical decision support tools, to benefit patients with glioblastoma and other brain tumours
